Titan Pharmaceuticals Inc

Titan Pharmaceuticals — IPO Roadshow (September 2018)

26 slides from Titan Pharmaceuticals's IPO roadshow presentation, Sep 4, 2018

  1. Slide 1: Titan Pharmaceuticals Corporate Presentation

    TITAN PHARMACEUTICALS CORPORATE PRESENTATION | SEPTEMBER 2018 © 2018 TITAN PHARMACEUTICALS INC. Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No. 333 - 226841 September 4, 2018

  2. Slide 2: Forward-looking statements

    This presentation contains forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 , as amended, or the Securities Act, and Section 21 E of the Securities Exchange Act of 1934 , or the Exchange Act . All statements other than statements of historical facts conta

  3. Slide 3: Free Writing Prospectus Statement

    This presentation highlights basic information about us and the offering to which this communication relates. Because it is a su mmary, it does not contain all of the information that you should consider before investing in our securities. We have filed a registration statement (including a prospect

  4. Slide 4: Offering Summary

    Exchange/Symbol NASDAQ:TTNP Offering Approximately $15 million Over - Allotment Option 15% Use of Proceeds Operations and other general corporate purposes, including building our infrastructure to commercialize Probuphine, conduct Phase IV trials required by the FDA and general working capital Under

  5. Slide 5: Titan Leadership

    TITAN LEADERSHIP RELEVANT EXPERIENCE Marc Rubin, M.D. Executive Chairman & Director • 12 years with Titan • Former Head of Global R&D and member of the Board of Management at Bayer Pharma • Executive R&D and commercial responsibilities at GSK for 13 years • 28 years in the pharmaceutical industry fo

  6. Slide 6: Company Snapshot

    COMPANY SNAPSHOT Transforming into a commercial - stage company following reacquisition of Probuphine ® rights in the U.S. Lead product, Probuphine, is an implant formulation of buprenorphine for the long - term maintenance treatment of opioid use disorder (OUD) • Approved in U.S. and Canada, under

  7. Slide 7: ProNeura Long-Term Drug Delivery Platform

    PRONEURA LONG - TERM DRUG DELIVERY PLATFORM Drug is released continuously into patient's body through dissolution • Results in a stable level of medication in the blood, avoiding peaks and troughs of oral dosing • Around - the - clock long - term treatment (potentially 3 - 12 months) in outpatient s

  8. Slide 8: ProNeura-Based Products & Product Candidates

    PRONEURA - BASED PRODUCTS & PRODUCT CANDIDATES ROBUST PIPELINE Feasibility Programs • OUD – long term (up to 6 months) implant using a full new opioid antagonist • Malaria prophylaxis (in collaboration with Walter Reed Army Institute of Research and Southwest Research Institute) • Type 2 diabetes wi

  9. Slide 9: Addiction to Opioids: A Global Health Emergency

    ADDICTION TO OPIOIDS A GLOBAL HEALTH EMERGENCY 9 A severe, chronic, relapsing brain disease characterized by compulsive drug seeking and use, despite harmful consequences • Cravings, accompanied by lack of impulse control • Cycles of relapse and remission • Progressive, and if untreated often leads

  10. Slide 10: A Public Health Crisis Continuing to Spiral Out of Control

    A PUBLIC HEALTH CRISIS CONTINUING TO SPIRAL OUT OF CONTROL 10 Bleak New Estimates in Drug Epidemic: A Record 72,000 Overdose Deaths in 2017 – CDC and NYT, August 2018 “The death toll is higher than the peak yearly death totals from HIV, car crashes, or gun deaths.” -------------------------------- “

  11. Slide 11: Current MAT Paradigm: Challenge & Opportunity

    CURRENT MAT PARADIGM CHALLENGE & OPPORTUNITY 11 Buprenorphine is the gold standard • Approximately $2 billion annual sales of buprenorphine in U.S. Buprenorphine pharmacology: a safer, more effective, and more convenient treatment option • Controls withdrawal symptoms and cravings without inducing o

  12. Slide 12: Probuphine: A Novel Solution

    PROBUPHINE A NOVEL SOLUTION 12 Regulatory Status: • U.S. Food and Drug Administration (FDA) approved in Q2 - 2016 - Transformational buprenorphine treatment for OUD • Health Canada approved in Q2 - 2018 - Sublicensed to Knight Therapeutics Inc. • Currently under review by the European Medicines Agen

  13. Slide 13: Braeburn U.S. Probuphine Launch: Missed Opportunity

    BRAEBURN U.S. PROBUPHINE LAUNCH MISSED OPPORTUNITY 13 Initial U.S. commercialization timeline: • FDA approved in May 2016 • Launched by Braeburn in July 2016 Braeburn’s launch missed the mark • Failure to appropriately segment the market at launch • Inadequate systems to support distribution, reimbu

  14. Slide 14: MAT Access Is Starting to Increase

    MAT ACCESS IS STARTING TO INCREASE 14 • In the U.S., 50% of the patient population with OUD is still medically untreated • About 52,000 physicians, representing 5 % of the nation’s doctors, are currently certified to prescribe buprenorphine • About 6,000 physicians writing approximately 90% of bupre

  15. Slide 15: Treatment Landscape Is Evolving

    TREATMENT LANDSCAPE IS EVOLVING NEW TAILWINDS FOR THE RELAUNCH OF PROBUPHINE 15 The field is accelerating towards longer duration buprenorphine therapy • Initially led by Indivior PLC’s SUBLOCADE™ (buprenorphine extended - release) monthly depot injection, approved by FDA in November 2017 Indivior i

  16. Slide 16: Titan Is Transforming Development-Stage to Commercial-Stage

    Build a commercial infrastructure to support growth • Establish a small (~10 people) commercial and medical affairs team with expertise in: - Sales - Marketing and supply chain logistics - Medical science liaison and training functions - REMS program management - Third party payer and medical access

  17. Slide 17: Recent Molteni Partnership

    RECENT MOLTENI PARTNERSHIP PROVIDES GLOBAL PHARMACEUTICAL INDUSTRY EXPERTISE 17 Molteni • Recognized leader in the field of drug dependence, operating in more than 30 countries • Strong track record of launching and commercializing innovative pain and addiction pharma products • Federico Seghi Recli

  18. Slide 18: Focused Segmentation Strategy: U.S. Relaunch

    FOCUSSED SEGMENTION STRATEGY U.S. RELAUNCH 18 Certified Healthcare Providers Residential Treatment Facilities Criminal Justice System Academic Addiction Programs

  19. Slide 19: Certified Healthcare Providers

    CERTIFIED HEALTHCARE PROVIDERS ENGAGE & LEVERAGE THE TOP - TIER 19 Engage the top tier subgroup of 75 - 100 highest Probuphine prescribers Certified Healthcare Providers Residential Treatment Facilities Academic Addiction Programs Criminal Justice System • Enhance reimbursement support and pharmacy

  20. Slide 20: Residential Treatment Facilities

    RATIONALE & APPROACH 20 RESIDENTIAL TREATMENT FACILITIES Certified Healthcare Providers Residential Treatment Facilities Academic Addiction Programs Criminal Justice System • High rates of post - discharge relapse, including overdose events and related deaths • Growing pressure to include MAT in res

  21. Slide 21: Academic Addiction Programs

    ACADEMIC ADDICITION PROGRAMS INITIAL TARGETING 21 Certified Healthcare Providers Residential Treatment Facilities Academic Addiction Programs Criminal Justice System Thousands of OUD Patients are Treated Annually in Academic Programs Across the U.S. • Initially target selected academic centers, leve

  22. Slide 22: Criminal Justice System

    CRIMINAL JUSTICE SYSTEM LARGE OPPORTUNITY FOR PROBUPHINE 22 “Incarceration is an important opportunity to treat opioid addiction*” – NIDA 2017 • Less than 1% of U.S. prisons and jails allow access to medication for OUD, and only 11% of inmates who need OUD treatment receive any form of it • New rese

  23. Slide 23: U.S. Regulatory Strategy: Potential for Label Expansion

    New FDA guidance on MAT for opioid addiction * • Encourages development of longer - acting formulations • Acknowledges the need for new drugs that don’t end addiction, but help with aspects of it, such as cravings, or overdoses, with the goal remaining complete abstinence Evaluate possible options f

  24. Slide 24: Capitalization Table

    CAPITALIZATION TABLE 24 Capitalization Table (As of 08/10/2018) # of Shares WAEP $ Value % of Fully Diluted Common Shares Outstanding (Directors & Officers) 481,854 1.70% Common Shares Outstanding (Other) 20,721,890 72.94% Total Common Shares Outstanding 21,203,744 Warrants 1,708,181 $2.37 $4,042,97

  25. Slide 25: In Summary

    IN SUMMARY 25 ProNeura: Unique and compelling long - term drug delivery platform Probuphine: Only product on market to provide six - month, continuous, non - fluctuating blood levels of buprenorphine for maintenance treatment of OUD U.S. Commercialization: Probuphine relaunch in early stages Partner

  26. Slide 26: Titan Pharmaceuticals

    TITAN PHARMACEUTICALS CORPORATE PRESENTATION | SEPTEMBER 2018 © 2018 TITAN PHARMACEUTICALS INC.

Titan Pharmaceuticals — IPO Roadshow (September 2018) on 6ix